KAS
CPRX

Kestra Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Kestra Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$988K Buy
39,901
+742
+2% +$17.7K ﹤0.01% 1742
2025
Q4 		$914K Sell
39,159
-20
-0.1% -$446 ﹤0.01% 1725
2025
Q3 		$772K Buy
+39,179
New +$806K ﹤0.01% 1766
2021
Q1 		– Sell
-22,000
Closed -$75K – 1888
2020
Q4 		$75K Buy
+22,000
New +$73.9K ﹤0.01% 1798

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Kestra Advisory Services's CPRX Position: Q1 2026 in Review

Kestra Advisory Services increased its Catalyst Pharmaceutical (CPRX) stake by 1.9% in Q1 2026, buying an estimated $17.7K and bringing the position to 39,901 shares worth $988K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Kestra Advisory Services first reported a position in CPRX in Q4 2020 and has held it in 4 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Kestra Advisory Services held 39,901 shares of Catalyst Pharmaceutical worth $988K as of Q1 2026.
  • Kestra Advisory Services bought 742 Catalyst Pharmaceutical shares in Q1 2026, an estimated $17.7K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #1742 holding.
  • Kestra Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2020 and has held it in 4 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.